Corporate Profile for Organogenesis, dated Nov. 1, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones Dow Jones the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202] See : Finance News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date: Nov. 1, 1996
Company Name: Organogenesis Inc.
Address: 150 Dan Road
Canton, Ma 02021
Main Telephone
Number: 617/575-0775
Chief Executive
Officer: Herbert Stein
Investor Relations
Contact: Carol Hausner
Business number: 617/575-0775
Public Relations
Contact: Carol Hausner
Business number: 617/575-0775
Trading Symbol: ORG
Industry: Biotechnology
Company description: Organogenesis organogenesis /or·ga·no·gen·e·sis/ (or?gah-no-jen´e-sis) the origin and development of organs.organogenet´ic or·gan·o·gen·e·sis n. The formation and development of the organs of living things. Inc. designs, develops and manufactures innovative medical therapeutics comprised of living cells and natural connective tissue components. The company's products are designed to encourage the body's natural tissue-healing processes by promoting new growth which can maintain, improve or restore biological function. HIGHLIGHTS: --Organogenesis' lead product, Apligraf (formerly Graftskin), has progressed from the laboratory, through clinical trials and manufacturing scale-up, and is now under review by the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for marketing approval. --Apligraf therapy has a potential market of over 13 million patients worldwide. --Organogenesis has entered into an agreement with Sandoz Ltd. granting Sandoz global marketing rights to Apligraf. Organogenesis receives royalties on all Apligraf sales, as well as a per unit manufacturing payment. Additionally, Organogenesis receives milestone payments, research support and equity investments. Sandoz bears all sales and marketing costs worldwide, as well as all responsibility and costs for product registration outside the U.S. --Organogenesis has developed expertise in four technological areas: cell culture, connective tissue science, cryopreservation cryopreservation /cryo·pres·er·va·tion/ (-prez?er-va´shun) maintenance of the viability of excised tissue or organs by storing at very low temperatures. cry·o·pres·er·va·tion n. and transplantation immunobiology. These technological strengths are not only an important part of Apligraf's development, but are also integral components of the company's product pipeline. For example, Organogenesis' expertise in the procurement, culture and optimization of difficult-to-culture cell types has led to the formation of a research collaboration with Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world for the development of a liver-assist device. CONTACT: Organogenesis |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion